Torrent Pharma’s Chronic Care Edge

Torrent Pharma looks valuable for shareholders because most of its India business comes from chronic care, a segment that gives repeat prescriptions, steadier demand, and better visibility than one-time treatments. The company’s recent FY26 numbers also show strong momentum: Q3 revenue was ₹3,303 crore, up 17.6% year on year, while net profit rose 26% to ₹635 crore, and EBITDA reached ₹1,088 crore with a 33% margin. This matters because chronic therapies such as cardiac, diabetes, and CNS usually build long-term customer retention. Torrent already gets about 75% of its India business from chronic care, so it is well placed to benefit from India’s rising burden of lifestyle diseases and the shift toward lifelong medication. That gives the stock a structural growth story rather than a short-lived sales spike. There are, however, some risks for shareholders. The business is becoming larger and more complex after the JB Pharma acquisition, and while that can lift scale, it also raises integration risk and makes near-term execution important. Valuation can also remain demanding when the market prices in strong growth, so any slowdown in India sales, margin pressure, or acquisition-related costs may weigh on returns. On balance, Torrent Pharma appears beneficial for long-term shareholders because it combines sticky chronic demand, strong earnings growth, and a visible expansion path. The downside is that the market may already expect a lot, so future gains will depend on disciplined execution and sustaining growth after the acquisition.